Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2023 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Liabilities and Shareholders Equity of $1.2 billion for Q1 2026, down 12.95% year-over-year from $1.4 billion in Q1 2025, and little changed quarter-over-quarter from $1.2 billion in Q4 2025.
Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 12.95% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $5.3 billion (up 95.69% YoY), while the FY2025 annual figure was $1.2 billion, down 8.74% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, roughly flat from $1.2 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.8 billion in Q4 2023, with the low at $1.2 billion in Q1 2026.
- The 4-year median for Liabilities and Shareholders Equity is $1.4 billion (2025), against an average of $1.4 billion.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity dropped 25.14% in 2024, then declined 8.74% in 2025.
- Indivior Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.8 billion in 2023, then fell by 25.14% to $1.3 billion in 2024, then fell by 8.74% to $1.2 billion in 2025, then fell by 0.33% to $1.2 billion in 2026.
- Business Quant data shows INDV's Liabilities and Shareholders Equity at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 6.18 Bn |
| 10 | Indivior Pharmaceuticals | 4.57 Bn | 4.35 Bn | 294.00 Mn | 1.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Bn |
| Mar 31, 2026 | 1.20 Bn |
| Dec 31, 2025 | 1.20 Bn |
| Sep 30, 2025 | 1.42 Bn |
| Jun 30, 2025 | 1.45 Bn |
| Mar 31, 2025 | 1.38 Bn |
| Dec 31, 2024 | 1.32 Bn |
| Dec 31, 2023 | 1.76 Bn |